// App-Quantinova.ai

EP633 : PIRTOBRUTINIB (LOXO-305), A NEXT GENERATION, HIGHLY SELECTIVE, NON-COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

Researchers

Presenter

  • Lindsey Roeker

Principal Investigators

  • Catherine C. Coombs

  • Nirav N. Shah

  • Nicole Lamanna

  • Ewa Lech-Maranda

  • Toby A Eyre

  • Jennifer A Woyach

  • William G Wierda

  • Chan Y. Cheah

  • Manish R. Patel

  • Bita Fakhri

  • Minal A. Barve

  • Constantine S. Tam

  • David Lewis

  • James N. Gerson

  • Alvaro Alencar

  • Justin Taylor

  • Omar Abdel-Wahab

  • Paolo Ghia

  • Stephen J. Schuster

  • Jessica Chen

  • Binoj Nair

  • Nora C. Ku

  • Matthew S. Davids

  • Jennifer R. Brown

  • Wojciech Jurczak

  • Anthony R. Mato

Medical Centers

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

  • Plymouth Hospitals NHS Trust - Derriford Hospital ,Plymouth,United Kingdom

  • Herbert Irving Comprehensive Cancer Center, Columbia University ,New York,Vereinigte Staaten

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States

  • Dana-Farber Cancer Institute and Harvard Medical School,Boston, Massachusetts,United States

  • Mary Crowley Cancer Research,Dallas,United States

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center,Oxford,United Kingdom

  • Linear Clinical Research/Sir Charles Gairdner Hospital, Nedlands, Australia

  • University of California, San Francisco, San Francisco, California, United States

  • Loxo Oncology at Lilly,Stamford, CT,United St

  • University of Miami Miller School of Medicine, Miami, Florida, United States

  • Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne ,Melbourne,Australia

  • Institute of Hematology and Transfusion Medicine, Warsaw, Poland

  • Eli Lilly and Company Indianapolis IN United States

  • Florida Cancer Specialists/Sarah Cannon Research Institute,Sarasota,Vereinigte Staaten

  • Swedish Cancer Institute, Seattle, Washington, United States

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Medical College of Wisconsin,Brookfield, Wisconsin,United States

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

Locations

  • Poland

  • United States

  • United Kingdom

  • Australia

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

Biomarkers

  • Bruton tyrosine kinase

  • Progesterone receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • I/II

Study Id's

  • NCT03740529

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved